Saar Gill at ASCO 2017 via ASH on YouTube

Ris­ing Penn star Saar Gill gets fund­ing for a next-gen CAR-T start­up, adding a new weapon to the mix

Ear­li­er this month, the Uni­ver­si­ty of Penn­syl­va­nia’s Saar Gill turned up at AS­CO to present new da­ta demon­strat­ing that a com­bi­na­tion of Im­bru­vi­ca with No­var­tis’ next-gen CAR-T CTL119 proved very ef­fec­tive in treat­ing par­tic­u­lar­ly lethal cas­es of chron­ic lym­pho­cyt­ic leukemia, wip­ing out all signs of the dis­ease in 8 of 9 treat­ment-re­sis­tant pa­tients en­rolled in an ex­plorato­ry study.

But Gill’s been par­tic­u­lar­ly busy on the CAR-T front, and not just in new re­search work. He’s al­so been en­list­ing some mar­quee in­vestors on a new start­up project that will aim at mak­ing a ma­jor new ad­vance in the field.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.